Canagliflozin
Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
Sold as Vokanamet · INVOKANA · INVOKAMET
- Drug class
- Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 118
Overview
Canagliflozin is an active pharmaceutical ingredient in the Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors group (A10BK). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 101 | May 29, 2026 |
| CA Canada | Health Canada | 15 | May 29, 2026 |
| EU European Union | EMA | 2 | December 18, 2025 |
GBUnited Kingdom· MHRA
101 products
Uses
Vokanamet is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise: • in patients insufficiently controlled on their maximally tolerated doses of metformin alone • in combination with other medicinal products for the treatment of diabetes, in patients insufficiently controlled with metformin and these medicinal products • in patients already being treated with the combination of canagliflozin and metformin as separate tablets.
1.
How to take
CACanada· Health Canada
15 products
Uses
Monotherapy:
INVOKANA® (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.
Add-on combination:
INVOKANA (canagliflozin) is indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with: • metformin • sulfonylurea (with or without metformin) • pioglitazone with metformin • metformin and sitagliptin • insulin (with or without metformin) when the therapy listed above, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS).
Add-On Combination in Patients with Established Cardiovascular Disease:
INVOKANA is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).
EUEuropean Union· EMA
2 products
Uses
Invokana is indicated for the treatment of adults and children aged 10 years and older with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes.
1. 3
How to take
Drug interactions
Known interactions involving Canagliflozin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 305. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB002420716 · revised May 15, 2026
- [2]Health Canada (DPD) · 02425483 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/002649 · revised December 18, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.